{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EXTEND&page=5",
    "query": {
      "intervention": "EXTEND",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 5818,
    "total_pages": 582,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EXTEND&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EXTEND&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T07:59:30.154Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00974974",
      "title": "A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "IPX066",
          "type": "DRUG"
        },
        {
          "name": "IR CD-LD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Impax Laboratories, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 471,
      "start_date": "2009-09",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-10-18T07:59:30.154Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00974974"
    },
    {
      "nct_id": "NCT01158079",
      "title": "Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ALN-VSP02",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2010-07",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2012-10-12",
      "last_synced_at": "2026-10-18T07:59:30.154Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158079"
    },
    {
      "nct_id": "NCT03709888",
      "title": "Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chemotherapy-induced Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Memantine XR-pregabalin combination therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Saint John's Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-07-09",
      "completion_date": "2021-04-29",
      "has_results": false,
      "last_update_posted_date": "2022-04-06",
      "last_synced_at": "2026-10-18T07:59:30.154Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03709888"
    },
    {
      "nct_id": "NCT00891020",
      "title": "A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "tocilizumab [RoActemra/Actemra]",
          "type": "DRUG"
        },
        {
          "name": "Nonbiologic DMARDs of investigator's choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 886,
      "start_date": "2009-05",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2012-10-25",
      "last_synced_at": "2026-10-18T07:59:30.154Z",
      "location_count": 227,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00891020"
    },
    {
      "nct_id": "NCT03242538",
      "title": "Prehabilitation for Pelvic Cancer: Changes in Setup Variability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pelvic Cancer"
      ],
      "interventions": [
        {
          "name": "Pelvic Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2017-06-23",
      "completion_date": "2019-01-17",
      "has_results": false,
      "last_update_posted_date": "2019-09-11",
      "last_synced_at": "2026-10-18T07:59:30.154Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03242538"
    },
    {
      "nct_id": "NCT02616315",
      "title": "Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Weight Regain Post Bariatric Surgery"
      ],
      "interventions": [
        {
          "name": "Naltrexone HCl/Bupropion HCl Placebo",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone HCl/Bupropion HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-02",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2016-04-08",
      "last_synced_at": "2026-10-18T07:59:30.154Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02616315"
    },
    {
      "nct_id": "NCT04781140",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "100mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "48 Months",
        "maximum_age": "69 Months",
        "sex": "ALL",
        "summary": "48 Months to 69 Months"
      },
      "enrollment_count": 286,
      "start_date": "2024-03-19",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-18T07:59:30.154Z",
      "location_count": 54,
      "location_summary": "Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more",
      "locations": [
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04781140"
    },
    {
      "nct_id": "NCT06089291",
      "title": "Persona IQ Cohort Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Osteo Arthritis Knee",
        "Knee Arthritis",
        "Monitoring Orthopedic Devices",
        "Total Knee Arthroplasty",
        "Total Knee Replacement"
      ],
      "interventions": [
        {
          "name": "Persona IQ",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Zimmer Biomet",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2024-02-20",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-18T07:59:30.154Z",
      "location_count": 4,
      "location_summary": "Granger, Indiana • St Louis, Missouri • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Granger",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06089291"
    },
    {
      "nct_id": "NCT01590459",
      "title": "24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "VX-509",
          "type": "DRUG"
        },
        {
          "name": "VX-509 matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 359,
      "start_date": "2012-04",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2015-11-20",
      "last_synced_at": "2026-10-18T07:59:30.154Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01590459"
    },
    {
      "nct_id": "NCT00864617",
      "title": "A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Nifedipine Extended Release tablets 60 mg, single dose",
          "type": "DRUG"
        },
        {
          "name": "ADALAT® CC Extended Release Tablets 60 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 84,
      "start_date": "2005-05",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2010-08-17",
      "last_synced_at": "2026-10-18T07:59:30.154Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00864617"
    }
  ]
}